CANCER DRUG DEVELOPMENT PIPELINE
Oncology Drug Pipeline & Cancer Clinical Trials
Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
sigvotatug vedotin (PF-08046047) | Project advanced
Advanced Solid Tumors (Biologic)
Integrin beta-6-directed antibody-drug conjugate
vepdegestrant (ARV-471) + CDK4 (PF-07220060) | Project advanced
ER+/HER2- 1L Metastatic Breast Cancer
CDK 4 kinase inhibitor ER-targeting PROTAC protein degrader
PF-07820435 | Project advanced
Solid Tumors
STING agonist
PF-08046045 (SGN-35T) | New project
Advanced Solid Tumors and Lymphomas (Biologic)
CD-30 directed antibody-tripeptide MMAE conjugate
PF-08046050 (SGN-CEACAM5C) | New project
Advanced Solid Tumors (Biologic)
CEACAM5-directed antibody-drug conjugate
PF-08046040 (SEA-CD70) | New project
Myelodysplastic Syndrome and Acute Myeloid Leukemia (Biologic)
Non-fucosylated CD70-directed antibody
PF-08046054 (SGN-PDL1V) | New project
Advanced Solid Tumors (Biologic)
PD-L1-directed antibody-drug conjugate
PF-08046052 (SGN-EGFRd2) | New project
Advanced Solid Tumors (Biologic)
EGFR-targeted bispecific gamma delta T-cell engager
felmetatug vedotin (PF-08046048) (SGN-B7H4V) | New project
Advanced Solid Tumors (Biologic)
B7H4-directed antibody-drug conjugate
PF-08046049 (SGN-BB228) | New project
Advanced Melanoma and Other Solid Tumors (Biologic)
CD228-directed antibody-Anticalin bispecific protein
TIVDAK (tisotumab vedotin) | New project
Recurrent or Metastatic Cervical Cancer (Biologic)
Tissue Factor-directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | New project
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate
TUKYSA (tucatinib) | New project
HER2+ Gastrointestinal Cancers (SGNTUC-024)
HER2 tyrosine kinase inhibitor
PADCEV (enfortumab vedotin) | New project
Urothelial Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate
PF-07248144 + PF-07220060 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier + CDK4 inh
PF-07799544 | New project
Solid Tumors
MEK brain penetrant inhibitor
PF-07220060 + enzalutamide | New project
Prostate Cancer
CDK4 inhibitor
PF-07104091 | New project
Ovarian Cancer
CDK2 inhibitor
PF-07799933 | New project
Solid Tumors
BRAF Class 1 and Class 2 inhibitor
PF-07104091 + PF-07220060 | New project
Breast Cancer Metastatic
CDK2 + CDK4 inhibitors
PF-07284892 | New project
Solid Tumors
SHP2 tyrosine phosphatase inhibitor
PF-07248144 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier
PF-07104091 | New project
Breast Cancer Metastatic
CDK2 inhibitor
PF-06940434 | New project
Solid Tumors (Biologic)
Integrin alpha-V/beta-8 antagonist
atirmociclib (PF-07220060) | New project
1L Metastatic Breast Cancer
CDK4 inhibitor
Disitamab vedotin (DV) | New project
Locally Advanced or Metastatic Solid Tumors with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
Disitamab vedotin (DV) | New project
2L+ Urothelial Cancer with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | New project
Locally Advanced or Metastatic Solid Tumors with HER2 Alterations
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
2L+ HER2+ mBC (HER2CLIMB-04)
HER2 tyrosine kinase inhibitor
TIVDAK (tisotumab vedotin) | New project
Advanced Solid Tumors (Biologic)
TF directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | New project
Locally Advanced or Metastatic Solid Tumors (Biologic)
Nectin-4 directed antibody-drug conjugate
mevrometostat (PF-06821497) + enzalutamide | New project
Prostate Cancer
EZH2 inhibitor
maplirpacept (TTI-622) | New project
Hematological Malignancies (Biologic)
CD47-SIRPa fusion protein
vepdegestrant (ARV-471) | New project
ER+/HER2- Early Breast Cancer
ER-targeting PROTAC protein degrader
ADCETRIS (brentuximab vedotin) | Project advanced
Diffuse Large B-Cell Lymphoma (DLBCL) (Biologic)
CD30-directed antibody-drug conjugate
atirmociclib (PF-07220060) | Project advanced
2L Metastatic Breast Cancer
CDK4 inhibitor
sigvotatug vedotin (PF-08046047) | Project advanced
2L Non-Small Cell Lung Cancer (NSCLC) (SGNB6A-002) (Biologic)
Integrin beta-6-directed antibody-drug conjugate
disitamab vedotin (DV) | New project
1L HER2 (=IHC1+) Metastatic Urothelial Cancer (SGNDV-001) (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | New project
1L HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
1L HER2+ Maintenance Metastatic Breast Cancer (HER2CLIMB-05)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
2L/3L HER2+ Metastatic Breast Cancer (HER2CLIMB-02)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
HER2+ Adjuvant Breast Cancer (CompassHER2 RD)
HER2 tyrosine kinase inhibitor
PADCEV (enfortumab vedotin) | New project
Cisplatin-Eligible Muscle-Invasive Bladder Cancer (EV-304) (Biologic)
Nectin-4 directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | New project
Cisplatin-Ineligible/Decline Muscle-Invasive Bladder Cancer (EV-303) (Biologic)
Nectin-4 directed antibody-drug conjugate
IBRANCE + vepdegestrant (ARV-471) | New project
ER+/HER2- Metastatic Breast Cancer (VERITAC 3)
CDK 4,6 kinase inhibitor ER-targeting PROTAC protein degrader
vepdegestrant (ARV-471) | New project
ER+/HER2- Metastatic Breast Cancer (VERITAC 2) (FAST TRACK - U.S.)
ER-targeting PROTAC protein degrader
ELREXFIO (elranatamab-bcmm) | Project advanced
Multiple Myeloma Resistant Refractory (MM-32) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Transplant-Ineligible (MM-6) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (MM-7) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Multiple Myeloma Double-Class Exposed (MM-5) (Biologic)
BCMA-CD3 bispecific antibody
BRAFTOVI (encorafenib) + ERBITUX (cetuximab) + chemotherapy | New project
1L BRAF-Mutant Metastatic Colorectal Cancer (BREAKWATER)
BRAF kinase inhibitor
TALZENNA (talazoparib) | New project
Combo w/ XTANDI (enzalutamide) for DNA Damage Repair (DDR)-Deficient Metastatic Castration Sensitive Prostate Cancer (TALAPRO-3)
PARP inhibitor
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) | New project
Non-Muscle-Invasive Bladder Cancer (CREST) (Biologic)
Anti-PD-1
IBRANCE (palbociclib) | New project
ER+/HER2+ Metastatic Breast Cancer(PATINA)
CDK 4,6 kinase inhibitor
- 00 Phase 1
- 00 Phase 2
- 00 Phase 3
- 00 Registration
- 00 Total